Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
H. Ballentine Carter MD

H. Ballentine Carter MD

Professor of Urology, Oncology, Johns Hopkins Medicine, Baltimore, Maryland; Director, Division of Adult Urology, Brady Urological Institute

Dr. Carter is a Professor of Urology, James Buchanan Brady Urological Institute at Johns Hopkins School of Medicine.  He was born in Lake City, S.C.  He graduated from Furman University in Greenville, S.C. with a B.S. in biology and received the Distinguished Alumni Award from Furman University in 2005.  He earned his M.D. degree from the Medical University of S.C. in 1981  and completed his urology residency at the New York Hospital-Cornell Medical Center in 1987.  In 1989 Dr. Carter completed an AUA scholarship in oncology at Johns Hopkins and joined their urology facility.

In 1998, Dr. Carter was promoted to Professor of Urology and Oncology at the Johns Hopkins School of Medicine where he is Director of Adult Urology.  He specializes in the management of prostate disease with a focus on prostate cancer.  Dr. Carter established an Active Surveillance program for prostate cancer at Johns Hopkins in 1995 that has become one of the largest and longest running longitudinal studies of this kind.

Dr. Carter  is a Diplomate of the American Board of urology and a member of the American Urological Association,  the Society of Urological Oncology, the American Society of Clinical Oncologists, and the American Association of Genitourinary Surgeons.

Recent Contributions to PracticeUpdate:

  1. Role of PSA Density on mpMRI and PI-RADS Score in Predicting Upstaging in Men on Active Surveillance
  2. Results of Prostate Cancer Screening in a Unique Cohort at 19 Years of Follow-Up
  3. Men With Clinically Detected, Localized Prostate Cancer Benefit From Radical Prostatectomy
  4. Long-Term Outcomes After Deferred Radical Prostatectomy in Men Initially Managed by Active Surveillance
  5. Active Surveillance for Low and Intermediate Risk Prostate Cancer
  6. Role of Surveillance Biopsy With No Cancer as a Prognostic Marker for Reclassification
  7. Transition From Active Surveillance to Watchful Waiting Among Men With Very Low–Risk Prostate Cancer
  8. Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance
  9. Active Surveillance for Intermediate-Risk Prostate Cancer Improves Survival Outcomes
  10. USPSTF Screening Recommendations and Impact on Prostate Cancer Incidence and PSA Testing

Recently Updated